Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

SCRT i TNT med eller uden chlorophyllin (SCOTCH)

18. september 2026 opdateret af: Tata Memorial Centre

Kort kursus stråleterapi baseret total neoadjuverende terapi med eller uden chlorophyllin (SCOTCH-undersøgelse)

The goal of this clinical trial is to see, if addition of chlorophyllin to neoadjuvant Chemo-radiotherapy can reduce the gastro-intestinal/genitourinary/hematological toxicity rates and improve the quality of life in patient's diagnosed with locally advanced rectal cancer.

This is a randomized placebo control trial, wherein participants randomized to Chlorophyllin arm will receive the drug of interest along with the standard treatment. Participants randomized to other arm will receive placebo along with the standard treatment.

Researchers will compare the difference between the outcomes from both the arms and will also observe the non-operative management success rates.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Detaljeret beskrivelse

The current standard treatment for locally advanced rectal cancer includes neoadjuvant (treatment given before Surgery) radiotherapy & chemotherapy followed by surgery if needed or wait and watch in patients whom tumour has completely regressed. It has been observed that even after receiving this intensive treatment patients, almost 70% of patients develop acute toxicity (during or within 3 months) of grade 2 or higher (needing medication for toxicity). This affects their treatment tolerance, completion and quality of life.

In this study Researchers are going to see if addition of drug Chlorophyllin (derived from green plant leaves) along with standard treatment would help in reducing the acute toxicity. Chlorophyllin is present in all green leaves of plants giving them green color. The drug is derived from green plant leaves. As it is a plant-based product it is safe for humans and has no known side effects of its own. This is a randomized study which has two arms; Arm 1 is test arm where participants will receive drug of interest (Chlorophyllin) and in other arm participants will receive Placebo. Upon successful completion of study, outcomes from both the study arm will be compared and participants will be followed by standard protocol for 3 years.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

76

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Maharashtra
      • Mumbai, Maharashtra, Indien, 400012
        • Tata Memorial Hospital
      • Navi Mumbai, Maharashtra, Indien, 410210
        • Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 90 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age > 18 years.

  • Histologically confirmed diagnosis of adenocarcinoma of the rectum.

  • Clinical Stage II/III (T2-3, 4b: adherent to prostate, SV or post vagina but not grossly invading, N0-2) based on MRI.

  • Non-circumferential tumours with craniocaudal length <7 cm

  • The tumours of the lower rectum, or starting up to 7 cm from the anal verge.

  • No evidence of distant metastases on CT Chest and Abdomen.

  • No prior pelvic radiation therapy

  • No prior chemotherapy or surgery for rectal cancer

  • Eastern Cooperative Oncology Group (ECOG) Performance status 0-2

  • Patients must read, agree to, and sign a statement of Informed Consent prior to participation in this study.

  • Eligible to receive one of the options of standard neoadjuvant chemotherapy as determined by the medical oncologist team.

    • Absolute neutrophil count (ANC) > 1.5 cells/mm3, hemoglobin (HGB) > 8.0 gm/dl, platelet (PLT) > 150,000/mm3.
    • Total bilirubin ≤ 1.5 x ULN (except in patients with Gilbert's Syndrome who must have total bilirubin ≤ 3.0 x ULN), aspartate aminotransferase (AST) ≤ 3 x ULN, alanine transaminase (ALT) ≤ 3 x ULN.

Exclusion Criteria:

  • Signet or mucinous histology cancer of rectum
  • Recurrent rectal cancer or previous pelvic radiotherapy
  • Primary unresectable rectal cancer.
  • Creatinine level greater than 1.5 times the upper limit of normal.
  • Patients who are unable to undergo an MRI.
  • Patients with a history of any arterial thrombotic event within the past 6 months. This includes angina (stable or unstable), MI, TIA, or CVA.
  • Ulcerative colitis or any other histologically confirmed inflammatory bowel disease.
  • Patients with a history of venous thrombotic episodes such as deep venous thrombosis, and pulmonary embolism occurring more than 6 months prior to enrollment may be considered for protocol participation, provided they are on stable doses of anticoagulant therapy. Similarly, patients who are anticoagulated for a trial fibrillation or other conditions may participate, provided they are on stable doses of anticoagulant therapy.
  • Patients with any other concurrent medical or psychiatric condition or disease which, in the investigator's judgment, would make them inappropriate candidates for entry into this study.
  • Poor reliability for follow up.
  • Ineligible as per eligibility criteria

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Chlorophyllin

Drug name: Sodium Copper Chlorophyllin Dosage form: Tablet Dosage: 750 mg Route of administration: Oral Frequency: Once daily in the morning before food. Duration: From 10-14 days before radiotherapy up to 3 months after the last dose of cytotoxic therapy

Additional Chlorophyllin tablet with Short Course radiotherapy based total neoadjuvant treatment +/- brachytherapy boost dose

Placebo komparator: Placebo

Drug Name: Placebo Dosage form: 1 Tablet Route of administration: Oral Frequency: Once daily in the morning before food. Duration: From 10-14 days before radiotherapy up to 3 months after the last dose of cytotoxic therapy

Additional Placebo tablet with Short Course radiotherapy based total neoadjuvant treatment +/- brachytherapy boost dose

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Acute Toxicity
Tidsramme: 3 months post-last cytotoxic therapy.

Incidence of grade 2 or higher Common Terminology Criteria for Adverse Events (CTCAE) acute gastro-intestinal (GI)/genitourinary (GI)/haematological toxicity (HT) in advanced rectal cancer.

Minimum value: Grade 1 Maximum value: Grade 5 Grade 1 late toxicity means a good outcome. Grade 2 or higher late toxicity means a worse outcome.

3 months post-last cytotoxic therapy.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Overall successful complete response rates
Tidsramme: 3 years

To estimate the 3-year overall complete response rates (clinical or pathological) and complete clinical response (cCR) at 24-36 weeks post TNT in whole cohort and if any difference between chlorophyllin and control arms.

3 years
Organ preservation rates
Tidsramme: 3 years

To estimate the 3-year organ preservation rates, TME free survival and if any difference between chlorophyllin & control arms.(by estimating patients who did not need surgery for rectal cancer (Total mesorectal excision; TME) at two years and if any difference between chlorophyllin and control arms.)

3 years
Disease free survival
Tidsramme: 3 years

To estimate the 3-year disease free survival, Distant metastasis free survival, loco-regional failure free survival, and overall survival rates in the whole cohort, and if any difference between two arms and between patients with successful non-operative management versus others.

3 years
Treatment related early and late toxicities
Tidsramme: 2 years

To compare treatment-related early and late toxicities (grade 2 Common Terminology Criteria for Adverse Events, version 5.0) for two years between the groups as (3).

Minimum value: Grade 1 Maximum value: Grade 5 Grade 1 late toxicity means a good outcome. Grade 2 or higher late toxicity means a worse outcome.

2 years
Estimation of surgical complications
Tidsramme: 30 days post surgery

To estimate surgical complications based on Clavien-Dindo classification. Minimum value: Grade 1 Maximum value: Grade 5 Grade 1 surgical complications means a good outcome. Grade 2 or higher surgical complications means a worse outcome.

30 days post surgery
Health related quality of life
Tidsramme: 2 years

To estimate and compare Health Related Quality of Life (QOL) between various groups as (3). (using quality of life questionnaires (QLQ) of European Organization for Research and Treatment of Cancer (EORTC)) These questionnaires will be filled by patient at six month interval of follow up.

2 years
Cost benefit with reduction in toxicity
Tidsramme: 2 years

The direct cost of per patient for various supportive medications, hospital admissions will be estimated in both arms and compared to see if any financial benefit of reduction in toxicity.

Record of medicines and details of hospitalization will be maintained.

2 years
Tumor Volume reduction kinetics
Tidsramme: 2 years

To study the correlation of tumour volume with used radiotherapy doses leading to a successful non-operative management versus not in the study group of patients.

2 years
To evaluate the timeline of Occurence
Tidsramme: 3 years

To evaluate the timeline of Occurence of grade 2/3 GI toxicities (namely rectal bleeding, rectal ulcer, rectal pain, tenesmus) during SCRT based TNT.

3 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Prof. Rahul Krishnatry, M.D., Tata Memorial Hospital

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

5. juli 2023

Primær færdiggørelse (Faktiske)

9. september 2025

Studieafslutning (Anslået)

9. september 2027

Datoer for studieregistrering

Først indsendt

10. april 2023

Først indsendt, der opfyldte QC-kriterier

3. maj 2023

Først opslået (Faktiske)

12. maj 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

23. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner